| Trial ID: | L3061 |
| Source ID: | NCT00236626
|
| Associated Drug: |
Topiramate
|
| Title: |
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Obesity|Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset
|
| Interventions: |
DRUG: topiramate
|
| Outcome Measures: |
Primary: Mean change in insulin sensitivity from baseline to Month 9. | Secondary: Mean change, baseline to Month 9, in body weight and composition, Body Mass Index (BMI), lipid profile, fasting glucose; blood pressure; safety evaluations (adverse events) during study.
|
| Sponsor/Collaborators: |
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-04
|
| Completion Date: |
2002-05
|
| Results First Posted: |
|
| Last Update Posted: |
2011-06-08
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00236626
|
